october, 2014

24oct12:00 pm1:00 pmBoston Young Investors Group/Biopharma


Event Details

This is a luncheon presentation with Arthur Tinkelenberg, CEO of Enumeral (OTCQB: ENUM).  Located in Cambridge, MA, Enumeral is a biopharmaceutical company focused on discovering and developing antibodies for the treatment of cancer and inflammatory diseases.


Company highlights include:


  •          Enumeral uses cells from the human immune system and a platform developed at MIT, Harvard, Whitehead Institute and MGH to discover rare antibodies that may have the characteristics essential to become a safe and effective drug
  •          The Company is focusing initially on the hot topic of cancer immunotherapy, where many major partnerships and financing deals have taken place over the last year and a large unmet medical need exists
  •          Enumeral has conducted proof-of-concept studies in collaboration with leading biotech/pharma companies and plans to enter two additional collaborations by mid-2015
  • PPO and reverse merger in August 2014

The format of this non-deal roadshow meeting is 15 minutes of networking, a 30-minute presentation over lunch, concluding with 15 minutes of Q&A.


(Friday) 12:00 pm - 1:00 pm


BWH, Shapiro Building

70 Francis St., Boston, MA